Becton, Dickinson & Co. has completed the spin-off of its diabetes business into a separate public company, Embecta. Becton, Dickinson shareholders received one Embecta share for every five of their securities. Effective today, Embecta shares began trading on the NASDAQ exchange under the ticker EMBC.